0 661

Cited 14 times in

Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS.

DC Field Value Language
dc.contributor.author이진성-
dc.date.accessioned2017-02-27T07:34:15Z-
dc.date.available2017-02-27T07:34:15Z-
dc.date.issued2016-
dc.identifier.issn1618-2642-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/146917-
dc.description.abstractA deficiency of α-galactosidase A causes Fabry disease (FD) by disrupting lipid metabolism, especially trihexosylceramide (THC). Enzyme replacement therapy (ERT) is clinically offered to FD patients in an attempt to lower the accumulated lipids. Studies on specific types of lipids that are directly or indirectly altered by FD are very scarce, even though they are crucial in understanding the biological process linked to the pathogenesis of FD. We performed a comprehensive lipid profiling of plasma and urinary lipids from FD patients with nanoflow liquid chromatography electrospray-ionization tandem mass spectrometry (nLC-ESI-MS/MS) and identified 129 plasma and 111 urinary lipids. Among these, lipids that exhibited alternations (>twofold) in patients were selected as targets for selected reaction monitoring (SRM)-based high-speed quantitation using nanoflow ultra-performance LC-ESI-MS/MS (nUPLC-ESI-MS/MS) and 31 plasma and 26 urinary lipids showed significant elevation among FD patients. Higher percentages of sphingolipids (SLs; 48% for plasma and 42% for urine) were highly elevated in patients; whereas, a smaller percentage of phospholipids (PLs; 15% for plasma and 13% for urine) were significantly affected. Even though α-galactosidase A is reported to affect THC only, the results show that other classes of lipids (especially SLs) are changed as well, indicating that FD not only alters metabolism of THC but various classes of lipids too. Most lipids showing significant increases in relative amounts before ERT decreased after ERT, but overall, ERT influenced plasma lipids more than urinary lipids.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent2265~2274-
dc.publisherSpringer-Verlag-
dc.relation.isPartOfANALYTICAL AND BIOANALYTICAL CHEMISTRY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHCase-Control Studies-
dc.subject.MESHChromatography, Liquid/methods*-
dc.subject.MESHEnzyme Replacement Therapy*-
dc.subject.MESHFabry Disease/drug therapy*-
dc.subject.MESHHumans-
dc.subject.MESHLipids/blood*-
dc.subject.MESHLipids/urine*-
dc.subject.MESHSpectrometry, Mass, Electrospray Ionization/methods*-
dc.subject.MESHalpha-Galactosidase/therapeutic use*-
dc.titleVariations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS.-
dc.typeArticle-
dc.publisher.locationGermany-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Clinical Genetics-
dc.contributor.googleauthorSeul Kee Byeon-
dc.contributor.googleauthorJin Yong Kim-
dc.contributor.googleauthorJin-Sung Lee-
dc.contributor.googleauthorMyeong Hee Moon-
dc.identifier.doi10.1007/s00216-016-9318-1-
dc.contributor.localIdA03227-
dc.relation.journalcodeJ00132-
dc.identifier.eissn1618-2650-
dc.identifier.pmid26873218-
dc.identifier.urlhttp://link.springer.com/article/10.1007/s00216-016-9318-1-
dc.subject.keywordEnzyme replacement therapy-
dc.subject.keywordFabry disease-
dc.subject.keywordLipid-
dc.subject.keywordNanoflow UPLC-ESI-MS/MS-
dc.subject.keywordTrihexosylceramide (THC)-
dc.contributor.alternativeNameLee, Jin Sung-
dc.contributor.affiliatedAuthorLee, Jin Sung-
dc.citation.volume408-
dc.citation.number9-
dc.citation.startPage2265-
dc.citation.endPage2274-
dc.identifier.bibliographicCitationANALYTICAL AND BIOANALYTICAL CHEMISTRY, Vol.408(9) : 2265-2274, 2016-
dc.date.modified2017-02-24-
dc.identifier.rimsid46483-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.